Stockreport

Roche and Zealand's Phase II obesity trial divides analyst opinion [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF Roche and Zealand Pharma's co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial, but the data has garnered mixed analyst reactio [Read more]